Introduction:
Dyadic International has partnered with Cygnus Technologies to develop a solution for the quantification of host cell proteins (HCPs) from C-1 cells. This partnership aims to enhance quality control in biopharmaceutical manufacturing by providing a fast and reliable method for monitoring HCPs.
- Cygnus Technologies has developed the C1 HCP ELISA Kit, which will be made available to Dyadic and Cygnus customers.
- HCP measurements are critical for ensuring drug efficacy, safety, and stability.
- The partnership demonstrates Dyadic’s commitment to keeping pace with industry standards for HCP analysis.
- The C1 HCP ELISA Kit is expected to facilitate the adoption of Dyadic’s C1 protein production platform.
- This partnership enables rapid and efficient production of antigens, monoclonal antibodies, and therapeutic proteins.
Conclusion:
The strategic partnership between Dyadic International and Cygnus Technologies will provide a solution for the quantification of host cell proteins in biopharmaceutical manufacturing. This development is crucial for ensuring the safety and efficacy of biopharmaceutical products. Furthermore, it showcases Dyadic’s commitment to staying at the forefront of industry standards and providing cost-effective solutions for protein production.
